@article{09b6bc073f184b5cbe018438e005fa40,
title = "Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy",
abstract = "Changes in fat distribution, dyslipidemia, disordered glucose metabolism, and lactic acidosis have emerged as significant challenges to the treatment of human immunodeficiency virus (HIV) infection. Over the past decade, numerous investigations have been conducted to better define these conditions, identify risk factors associated with their development, and test potential therapeutic interventions. The lack of standardized diagnostic criteria, as well as disparate study populations and research methods, have led to conflicting data regarding the diagnosis and treatment of metabolic and body shape disorders associated with HIV infection. On the basis of a review of the medical literature published and/or data presented before April 2006, we have prepared a guide to assist the clinician in the detection and management of these complications.",
author = "Wohl, {D. A.} and G. McComsey and P. Tebas and Brown, {T. T.} and Glesby, {M. J.} and D. Reeds and C. Shikuma and K. Mulligan and M. Dube and D. Wininger and J. Huang and M. Revuelta and J. Currier and S. Swindells and C. Fichtenbaum and M. Basar and M. Tungsiripat and W. Meyer and J. Weihe and C. Wanke",
note = "Funding Information: Potential conflicts of interest. D.A.W. has been a member of the speakers{\textquoteright} bureaus of Gilead Sciences, Bristol-Myers Squibb, Abbott Laboratories, Roche Pharmaceuticals, and Boehringer-Ingelheim and has received grant support from Abbott Laboratories, Gilead Sciences, and Roche Pharmaceuticals. G.M. has received recent research funding from GlaxoSmithKline, Bristol-Myers Squibb, Merck, and Gilead Sciences; has been a consultant for GlaxoSmithKline, Bristol-Myers Squibb, Gilead Sciences, and Abbott Laboratories; and has been a member of the speakers{\textquoteright} bureaus of GlaxoSmithKline, Bristol-Myers Squibb, Gilead Sciences, and Abbott Laboratories. P.T. has received recent research funding from Tibotec, Roche, Pfizer, VIRxSYS, and the National Institutes of Health and has consulted for Tibotec and Bristol-Myers Squibb. T.B. has received research support from Theratechnologies, Abbott Laboratories, and Reliant Pharmaceuticals; has been a consultant for Abbott Laboratories; and has been a member of the speakers{\textquoteright} bureaus of GlaxoSmithKline and Merck. M.J.G. has received research funding from Serono Laboratories; is an ad hoc consultant for Serono Laboratories; and has been a member of the speakers{\textquoteright} bureau of, as well as received honoraria from, Abbott Laboratories. C.S. has received research funding from Bristol-Myers Squibb, Schering Plough, and Gilead Sciences. K.M. has received research support from Insmed, Amgen, Procter and Gamble, and Aventis. M.D. is a consultant for Pfizer, GlaxoSmithKline, Gilead Sciences, Bristol-Myers Squibb, and Tibotec; has received a donation of a drug for research purposes from Bristol-Myers Squibb, Merck, and Abbott Laboratories; has received honoraria from, as well as been a member of the speakers{\textquoteright} bureaus of Pfizer, GlaxoSmithKline, Gilead Sciences, Bristol-Myers Squibb, and Merck; and has received research grants from Pfizer, GlaxoSmithKline, Gilead Sciences, Bristol-Myers Squibb, Merck, TheraTec, and Serono Laboratories. J.H. has received research funding from Novartis Pharmaceuticals and Pharmavite. J.C. has received research grants from Theratechnologies, Merck, GlaxoSmithKline, Tibotec, and Schering Plough and has been a consultant for GlaxoSmithKline, Abbott Laboratories, Ti-botec, Bristol-Myers Squibb, and Gilead Sciences. S.S. has received a research grant or a contract from Abbott Laboratories, Novartis Pharmaceuticals, and Pfizer and has received a research grant from and has been a consultant for Bristol-Myers Squibb. C.F. has received research funding from Abbott Laboratories, Gilead Sciences, Immtech, and Progenics; has been a member of the speakers{\textquoteright} bureaus of BIPI and Gilead Sciences; and has received honoraria and/or unrestricted grants from Merck, Solvay, Ti-botec, Abbott Laboratories, and BIPI. W.M. is employed by Quest Diagnostics. C.W. has received grant support from Serono, Gilead Sciences, and Abbott Laboratories; has been a consultant for Solvay and Par; and has been a member of the speakers{\textquoteright} bureaus of Merck and Abbott Laboratories. All other authors: no conflicts.",
year = "2006",
month = sep,
day = "1",
doi = "10.1086/507333",
language = "English (US)",
volume = "43",
pages = "645--653",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",
}